Company Filing History:
2 out of 114 
1 out of 37 Years Active: 2000-2017
Title: Tsutomu Hamuro: Innovator in Fibrinogen and Tissue Factor Pathway Inhibitor Technologies.
Introduction
Tsutomu Hamuro is a notable inventor based in Kumamoto, Japan. He has made significant contributions to the fields of biochemistry and medical technology, holding a total of 3 patents. His work primarily focuses on advancements in fibrinogen preparations and tissue factor pathway inhibitors.
Latest Patents
One of Hamuro's latest patents is for a solid fibrinogen preparation. This innovative preparation boasts improved solubility and can be rapidly utilized in clinical settings. The composition includes fibrinogen as the main ingredient, along with albumin, a nonionic surfactant, a basic amino acid or its salt, and at least two amino acids or their salts selected from acidic and neutral amino acids. This solid fibrinogen can be held on a medical material to create a supporting material that retains fibrinogen. Additionally, this supporting material can be combined with thrombin to produce a fibrin adhesive.
Another significant patent involves a process for preparing Tissue Factor Pathway Inhibitor (TFPI) using genetically engineered techniques. This process utilizes transformed animal cells where a DNA encoding human TFPI is introduced. The improvement in this method involves culturing the transformed cells in a medium supplemented with a sulfated polysaccharide, which protects the intact TFPI from protease cleavage during production.
Career Highlights
Throughout his career, Tsutomu Hamuro has worked with esteemed organizations such as the Chemo-Sero-Therapeutic Research Institute. His contributions to research and development in the medical field have been instrumental in advancing therapeutic technologies.
Collaborations
Hamuro has collaborated with notable colleagues, including Shintaro Kamei and Yuichi Kamikubo. These partnerships have further enhanced his research and innovation efforts.
Conclusion
Tsutomu Hamuro's work in fibrinogen and tissue factor pathway inhibitors showcases his dedication to advancing medical technology. His patents reflect a commitment to improving clinical applications and patient care.